ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Renal Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1621208
The effects of Shenkang suppository on kidney function and gut microbiota in nondialysis patients with chronic kidney disease stages 3-4: A randomized controlled trial
Provisionally accepted
- Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China, Xuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Chronic kidney disease (CKD) patients have high prevalence and mortality rates; however, current treatment options remain limited. The Shenkang suppository (SKS) is a traditional Chinese medicine used in the clinical management of CKD. Increasing evidence suggests a close relationship between the gut microbiome and CKD. We aimed to investigate the impact of SKS on kidney function and the gut microbiota in CKD stage 3-4 patients.Methods: It's a single-center randomized controlled trial (n=80). CKD stage 3-4 patients were randomly assigned at a 1:1 ratio to either the control group (n=40) or the SKS group (n=40) and followed for 8 weeks.Baseline data, clinical indicators, kidney markers, and stool samples were obtained from participants before and after treatment. The bacterial DNA was isolated from fecal samples and analyzed via highthroughput 16S rRNA sequencing.: A total of 34 patients in the SKS group and 36 in the control group completed the study. Kidney function in the control group significantly worsened after 8 weeks (P<0.05), whereas SKS had a positive effect on slowing the progression of kidney function decline. After 8 weeks of SKS intervention, the beneficial bacteria Coriobacteriaceae and Ruminococcaceae-Ruminococcus proliferated dramatically, whereas the abundance of the harmful bacteria Veillonellaceae decreased. Linear discriminant analysis (LDA) revealed that SKS treatment increased the proportion of Streptococcus and decreased the proportions of Planctomycetes, Spirochaetes, Rhodocyclales, Actinomycetaceae, Veillonellaceae, and Dechloromonas. These changes were not observed in the control group. Correlation analysis revealed a negative association between Bifidobacterium, Blautia, Enterococcaceae_Enterococcus, and clinical kidney function indicators, whereas Parabacteroides, Acinetobacter, Sutterella, Oscillospira, and Alistipes were positively correlated with kidney function. Conclusion: SKS could delay the progression of kidney function in CKD stage 3-4 patients, possibly by modulating the dysbiosis of the gut microbiota. The close associations between certain gut microbiota and clinical kidney function indicators suggest that the gut microbiota could serve as a new therapeutic target for CKD.
Keywords: Chronic Kidney Disease, Shenkang suppository, gut flora, Microbiota dysbiosis, Traditional Chinese medicine
Received: 30 Apr 2025; Accepted: 30 Jun 2025.
Copyright: © 2025 Zhang, Zhang, Xu, Waheed, Xu, Li and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dong Sun, Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China, Xuzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.